DNA methyltransferase 3 alpha and TET methylcytosine dioxygenase 2 restrain mitochondrial DNA-mediated interferon signaling in macrophages.

Cobo I, Isidoro Cobo, Tiffany N. Tanaka, Tanaka TN, Kailash Chandra Mangalhara, Chandra Mangalhara K, Addison Lana, Lana A, Yeang C, Calvin Yeang, Claudia Han, Han C, Johannes Schlachetzki, Schlachetzki J, Challcombe J, Jean Challcombe, Fixsen BR, Bethany R. Fixsen, Mashito Sakai, Sakai M, Li RZ, Rick Z. Li, Hannah Fields, Fields H, Mokry M, Michal Mokry, Randy G. Tsai, Tsai RG, Rafael Bejar, Bejar R, Prange K, Koen Prange, de Winther M, Menno de Winther, Gerald S. Shadel, Shadel GS, Christopher K. Glass, Glass CK
Immunity · 2022 · doi:10.1016/j.immuni.2022.06.022 · PMID:35931086 · PMC9718507
OA: closed
📄 Open PDF View on PubMed View at publisher

Abstract

Deleterious somatic mutations in DNA methyltransferase 3 alpha (DNMT3A) and TET mehtylcytosine dioxygenase 2 (TET2) are associated with clonal expansion of hematopoietic cells and higher risk of cardiovascular disease (CVD). Here, we investigated roles of DNMT3A and TET2 in normal human monocyte-derived macrophages (MDM), in MDM isolated from individuals with DNMT3A or TET2 mutations, and in macrophages isolated from human atherosclerotic plaques. We found that loss of function of DNMT3A or TET2 resulted in a type I interferon response due to impaired mitochondrial DNA integrity and activation of cGAS signaling. DNMT3A and TET2 normally maintained mitochondrial DNA integrity by regulating the expression of transcription factor A mitochondria (TFAM) dependent on their interactions with RBPJ and ZNF143 at regulatory regions of the TFAM gene. These findings suggest that targeting the cGAS-type I IFN pathway may have therapeutic value in reducing risk of CVD in patients with DNMT3A or TET2 mutations.

My notes (saved in your browser only)

Funding

funders
[{'doi': '10.13039/100007911', 'name': 'University of California San Diego', 'awards': []}]

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (1)

References (86)

Source provenance

crossref
last seen: 2026-08-15T06:29:40.561488+00:00
europepmc
last seen: 2026-08-16T09:21:09.727480+00:00
unpaywall
last seen: 2026-08-22T06:23:50.750314+00:00